Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis

References

• Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21–33.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Brill IK, Omel J, et al. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017 Jan 4;1(4):282–287.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol. 2013 Jul 10;31(20):2540–2547.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017 Jan 1;3(1):28–35.
   PubMed Web of Science ®Google Scholar
• Liu H, McCarthy P. New developments in post-transplant maintenance treatment of multiple myeloma. Semin Oncol. 2013 Oct;40(5):602–609.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yang F, Shen Y, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. J Natl Cancer Inst. 2015 Nov 18;108(3):djv342.
   PubMedGoogle Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017 Oct 10;35(29):3279–3289.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Anderson KC. Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis. 2003;8(4):337–343.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016 Apr 28;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020;60:457–476.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
   Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007 Jun 7;8:16.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Gay F, Schjesvold F, et al. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Jan 19;393(10168):253–264.
   PubMed Web of Science ®Google Scholar
• Zweegman S, Stege CAM, Haukas E, et al. Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial. Haematologica. 2020 Feb 13. DOI:https://doi.org/10.3324/haematol.2019.240374
   Google Scholar
• Dimopoulos MA, Špička I, Quach H, et al. Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial. J Clin Oncol. 2020 Dec 1;38(34):4030–4041.
   PubMed Web of Science ®Google Scholar
• Gay F, Jackson G, Rosiñol L, et al. Maintenance treatment and survival in patients with myeloma: a systematic review and network meta-analysis. JAMA Oncol. 2018 Oct 1;4(10):1389–1397.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Hillengass J, et al. NCCN guidelines insights: multiple myeloma, version 1.2020. J Natl Compr Canc Netw. 2019 Oct 1;17(10):1154–1165.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017 Oct 10;35(29):3279–3289.
   PubMed Web of Science ®Google Scholar
• Jones JR, Cairns DA, Gregory WM, et al. Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood Cancer J. 2016 Dec 9;6(12):e506.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609–2617.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Jacobus S, Vesole DH, et al. Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia. 2010;24(8):1406–1411.
   PubMed Web of Science ®Google Scholar
• Sun CY, Li JY, Chu ZB, et al. Efficacy and safety of bortezomib maintenance in patients with newly diagnosed multiple myeloma: a meta-analysis. Biosci Rep. 2017;37(4):BSR20170304.
   PubMedGoogle Scholar
• Peng L, Ye X, Zhou Y, et al. Meta-analysis of incidence and risk of peripheral neuropathy associated with intravenous bortezomib. Support Care Cancer. 2015;23(9):2813–2824.
   PubMed Web of Science ®Google Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4(5):349–360.
   PubMed Web of Science ®Google Scholar
• Gilmore TD. Multiple myeloma: lusting for NF-kappaB. Cancer Cell. 2007;12(2):95–97.
   PubMed Web of Science ®Google Scholar
• Shafqat M, Jamil F, Shah Z, et al. A systematic review and meta-analysis: efficacy and toxicity profile of ixazomib for treatment of multiple myeloma. Blood. 2018;132(Suppl. 1):5639.
   Google Scholar
• Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610–2618.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017 Jan 1;3(1):28–35.
   PubMed Web of Science ®Google Scholar
• Perrot A, Lauwers-Cances V, Corre J, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 Dec 6;132(23):2456–2464.
   PubMed Web of Science ®Google Scholar
• Balitsky AK, Karkar A, McCurdy A, et al. Maintenance therapy in transplant ineligible adults with newly-diagnosed multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2020;105(5):626–634.
   PubMed Web of Science ®Google Scholar
• Parrondo RD, Reljic T, Iqbal M, et al. Efficacy of proteasome inhibitor-based maintenance following autologous transplantation in multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2021;106(1):40–48.
   PubMed Web of Science ®Google Scholar